In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: Results from a randomized, 3-armed, double-blind clinical trial.

R.F. Van Vollenhoven; Mikkel Østergaard; M. Leirisalo-Repo; T. Uhlig; M. Jansson; Å. Klackenberg; K. Hutchinson; K. Franck-Larsson

In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: Results from a randomized, 3-armed, double-blind clinical trial.

R.F. Van Vollenhoven, Mikkel Østergaard, M. Leirisalo-Repo, T. Uhlig, M. Jansson, Å. Klackenberg, K. Hutchinson, K. Franck-Larsson

Originalsprog	Engelsk
Tidsskrift	Arthritis & Rheumatism
ISSN	0004-3591
Status	Udgivet - 2012

Adgang til dokumentet

http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=799&id=109746

Citationsformater

Van Vollenhoven, R. F., Østergaard, M., Leirisalo-Repo, M., Uhlig, T., Jansson, M., Klackenberg, Å., Hutchinson, K., & Franck-Larsson, K. (2012). In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: Results from a randomized, 3-armed, double-blind clinical trial. Arthritis & Rheumatism. http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=799&id=109746

In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: Results from a randomized, 3-armed, double-blind clinical trial. / Van Vollenhoven, R.F.; Østergaard, Mikkel; Leirisalo-Repo, M. et al.

I: Arthritis & Rheumatism, 2012.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Van Vollenhoven, RF, Østergaard, M, Leirisalo-Repo, M, Uhlig, T, Jansson, M, Klackenberg, Å, Hutchinson, K & Franck-Larsson, K 2012, 'In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: Results from a randomized, 3-armed, double-blind clinical trial.', Arthritis & Rheumatism. <http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=799&id=109746>

Van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, Uhlig T, Jansson M, Klackenberg Å et al. In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: Results from a randomized, 3-armed, double-blind clinical trial. Arthritis & Rheumatism. 2012.

Van Vollenhoven, R.F. ; Østergaard, Mikkel ; Leirisalo-Repo, M. et al. / In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: Results from a randomized, 3-armed, double-blind clinical trial. I: Arthritis & Rheumatism. 2012.

@article{7ddce269a7b0487b9df8ea42e211a825,

title = "In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: Results from a randomized, 3-armed, double-blind clinical trial.",

author = "{Van Vollenhoven}, R.F. and Mikkel {\O}stergaard and M. Leirisalo-Repo and T. Uhlig and M. Jansson and {\AA}. Klackenberg and K. Hutchinson and K. Franck-Larsson",

note = "Late-breaking abstract L10",

year = "2012",

language = "English",

journal = "Arthritis & Rheumatology",

issn = "2326-5205",

publisher = "Wiley",

}

TY - ABST

T1 - In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: Results from a randomized, 3-armed, double-blind clinical trial.

AU - Van Vollenhoven, R.F.

AU - Østergaard, Mikkel

AU - Leirisalo-Repo, M.

AU - Uhlig, T.

AU - Jansson, M.

AU - Klackenberg, Å.

AU - Hutchinson, K.

AU - Franck-Larsson, K.

N1 - Late-breaking abstract L10

PY - 2012

Y1 - 2012

M3 - Conference abstract in journal

SN - 2326-5205

JO - Arthritis & Rheumatology

JF - Arthritis & Rheumatology

ER -